Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Bone microenvironment signaling of cancer stem cells as a therapeutic target in metastatic prostate cancer.

Lee CH, Decker AM, Cackowski FC, Taichman RS.

Cell Biol Toxicol. 2019 Jun 27. doi: 10.1007/s10565-019-09483-7. [Epub ahead of print] Review.

PMID:
31250347
2.

The dopamine, serotonin and norepinephrine releasing activities of a series of methcathinone analogs in male rat brain synaptosomes.

Blough BE, Decker AM, Landavazo A, Namjoshi OA, Partilla JS, Baumann MH, Rothman RB.

Psychopharmacology (Berl). 2019 Mar;236(3):915-924. doi: 10.1007/s00213-018-5063-9. Epub 2018 Oct 20.

PMID:
30341459
3.

Effects of Occlusion on Periodontal Wound Healing.

Wang HL, Decker AM.

Compend Contin Educ Dent. 2018 Oct;39(9):608-612; quiz 613. Review.

PMID:
30299110
4.

Catatonia Due to Clozapine Withdrawal: A Case Report and Literature Review.

Boazak M, Cotes RO, Potvin H, Decker AM, Schwartz AC.

Psychosomatics. 2019 Jul - Aug;60(4):421-427. doi: 10.1016/j.psym.2018.07.010. Epub 2018 Jul 29. No abstract available.

PMID:
30268340
5.

Diarylureas Containing 5-Membered Heterocycles as CB1 Receptor Allosteric Modulators: Design, Synthesis, and Pharmacological Evaluation.

Nguyen T, Gamage TF, Decker AM, German N, Langston TL, Farquhar CE, Kenakin TP, Wiley JL, Thomas BF, Zhang Y.

ACS Chem Neurosci. 2019 Jan 16;10(1):518-527. doi: 10.1021/acschemneuro.8b00396. Epub 2018 Sep 20.

PMID:
30188693
6.

Potent and Selective Tetrahydroisoquinoline Kappa Opioid Receptor Antagonists of Lead Compound (3 R)-7-Hydroxy- N-[(1 S)-2-methyl-1-(piperidin-1-ylmethyl)propyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (PDTic).

Ondachi PW, Kormos CM, Runyon SP, Thomas JB, Mascarella SW, Decker AM, Navarro HA, Fennell TR, Snyder RW, Carroll FI.

J Med Chem. 2018 Sep 13;61(17):7525-7545. doi: 10.1021/acs.jmedchem.8b00673. Epub 2018 Aug 29.

PMID:
30117738
7.

Potent and Selective Tetrahydroisoquinoline Kappa Opioid Receptor Antagonists of Lead Compound (3 R)- N-[1 R)-1-(Cyclohexylmethyl)-2-methylpropyl]-7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (CDTic).

Kormos CM, Ondachi PW, Runyon SP, Thomas JB, Mascarella SW, Decker AM, Navarro HA, Fennell TR, Snyder RW, Carroll FI.

J Med Chem. 2018 Sep 13;61(17):7546-7559. doi: 10.1021/acs.jmedchem.8b00674. Epub 2018 Aug 29.

PMID:
30032602
8.

Discovery of a Potent, Selective, and Brain-Penetrant Small Molecule that Activates the Orphan Receptor GPR88 and Reduces Alcohol Intake.

Jin C, Decker AM, Makhijani VH, Besheer J, Darcq E, Kieffer BL, Maitra R.

J Med Chem. 2018 Aug 9;61(15):6748-6758. doi: 10.1021/acs.jmedchem.8b00566. Epub 2018 Jul 30.

9.

Periodontal Treatment in Cancer Patients: An Interdisciplinary Approach.

Decker AM, Taichman LS, D'Silva NJ, Taichman RS.

Curr Oral Health Rep. 2018 Mar;5(1):7-12. Epub 2018 Jan 27.

10.

Development of norepinephrine transporter reuptake inhibition assays using SK-N-BE(2)C cells.

Decker AM, Blough BE.

Heliyon. 2018 May 31;4(5):e00633. doi: 10.1016/j.heliyon.2018.e00633. eCollection 2018 May.

11.

Development of serotonin transporter reuptake inhibition assays using JAR cells.

Decker AM, Blough BE.

J Pharmacol Toxicol Methods. 2018 Jul - Aug;92:52-56. doi: 10.1016/j.vascn.2018.03.003. Epub 2018 Mar 16.

12.

Comparative neuropharmacology of N-(2-methoxybenzyl)-2,5-dimethoxyphenethylamine (NBOMe) hallucinogens and their 2C counterparts in male rats.

Elmore JS, Decker AM, Sulima A, Rice KC, Partilla JS, Blough BE, Baumann MH.

Neuropharmacology. 2018 Nov;142:240-250. doi: 10.1016/j.neuropharm.2018.02.033. Epub 2018 Mar 1.

PMID:
29501528
13.

CXCL12γ Promotes Metastatic Castration-Resistant Prostate Cancer by Inducing Cancer Stem Cell and Neuroendocrine Phenotypes.

Jung Y, Cackowski FC, Yumoto K, Decker AM, Wang J, Kim JK, Lee E, Wang Y, Chung JS, Gursky AM, Krebsbach PH, Pienta KJ, Morgan TM, Taichman RS.

Cancer Res. 2018 Apr 15;78(8):2026-2039. doi: 10.1158/0008-5472.CAN-17-2332. Epub 2018 Feb 5.

14.

MyD88-mediated innate sensing by oral epithelial cells controls periodontal inflammation.

Delitto AE, Rocha F, Decker AM, Amador B, Sorenson HL, Wallet SM.

Arch Oral Biol. 2018 Mar;87:125-130. doi: 10.1016/j.archoralbio.2017.12.016. Epub 2017 Dec 16.

15.

Mobile electronic versus paper case report forms in clinical trials: a randomized controlled trial.

Fleischmann R, Decker AM, Kraft A, Mai K, Schmidt S.

BMC Med Res Methodol. 2017 Dec 1;17(1):153. doi: 10.1186/s12874-017-0429-y.

16.

Synthesis and Evaluation of Orexin-1 Receptor Antagonists with Improved Solubility and CNS Permeability.

Perrey DA, Decker AM, Zhang Y.

ACS Chem Neurosci. 2018 Mar 21;9(3):587-602. doi: 10.1021/acschemneuro.7b00402. Epub 2017 Nov 20.

17.

The Effect of Implant-Induced Artifacts on Interpreting Adjacent Bone Structures on Cone-Beam Computed Tomography Scans.

Sheridan RA, Chiang YC, Decker AM, Sutthiboonyapan P, Chan HL, Wang HL.

Implant Dent. 2018 Feb;27(1):10-14. doi: 10.1097/ID.0000000000000684.

PMID:
29095787
18.

Fluorinated phenmetrazine "legal highs" act as substrates for high-affinity monoamine transporters of the SLC6 family.

Mayer FP, Burchardt NV, Decker AM, Partilla JS, Li Y, McLaughlin G, Kavanagh PV, Sandtner W, Blough BE, Brandt SD, Baumann MH, Sitte HH.

Neuropharmacology. 2018 May 15;134(Pt A):149-157. doi: 10.1016/j.neuropharm.2017.10.006. Epub 2017 Oct 6.

19.

Sympathetic Signaling Reactivates Quiescent Disseminated Prostate Cancer Cells in the Bone Marrow.

Decker AM, Jung Y, Cackowski FC, Yumoto K, Wang J, Taichman RS.

Mol Cancer Res. 2017 Dec;15(12):1644-1655. doi: 10.1158/1541-7786.MCR-17-0132. Epub 2017 Aug 16.

20.

Novel Diarylurea Based Allosteric Modulators of the Cannabinoid CB1 Receptor: Evaluation of Importance of 6-Pyrrolidinylpyridinyl Substitution.

Nguyen T, German N, Decker AM, Langston TL, Gamage TF, Farquhar CE, Li JX, Wiley JL, Thomas BF, Zhang Y.

J Med Chem. 2017 Sep 14;60(17):7410-7424. doi: 10.1021/acs.jmedchem.7b00707. Epub 2017 Aug 18.

21.

Prognostic Classification System for Implant Recession Defects.

Decker AM, Suárez-López Del Amo F, Urban IA, Miller PD Jr, Wang HL.

Implant Dent. 2017 Dec;26(6):848-852. doi: 10.1097/ID.0000000000000630.

PMID:
28753196
22.

Simple Tetrahydroisoquinolines Are Potent and Selective Kappa Opioid Receptor Antagonists.

Kormos CM, Ondachi PW, Runyon SP, Thomas JB, Mascarella SW, Decker AM, Navarro HA, Carroll FI.

ACS Med Chem Lett. 2017 May 25;8(7):742-745. doi: 10.1021/acsmedchemlett.7b00115. eCollection 2017 Jul 13.

23.

Discovery of Novel Proline-Based Neuropeptide FF Receptor Antagonists.

Nguyen T, Decker AM, Langston TL, Mathews KM, Siemian JN, Li JX, Harris DL, Runyon SP, Zhang Y.

ACS Chem Neurosci. 2017 Oct 18;8(10):2290-2308. doi: 10.1021/acschemneuro.7b00219. Epub 2017 Aug 9.

PMID:
28737888
24.

Development and validation of a high-throughput calcium mobilization assay for the orphan receptor GPR88.

Decker AM, Gay EA, Mathews KM, Rosa TC, Langston TL, Maitra R, Jin C.

J Biomed Sci. 2017 Mar 27;24(1):23. doi: 10.1186/s12929-017-0330-3.

25.

Biochemical Changes in the Niche Following Tumor Cell Invasion.

Decker AM, Cackowski FC, Jung Y, Taichman RS.

J Cell Biochem. 2017 Aug;118(8):1956-1964. doi: 10.1002/jcb.25843. Epub 2017 Apr 18. Review.

26.

Design, synthesis and pharmacological evaluation of 4-hydroxyphenylglycine and 4-hydroxyphenylglycinol derivatives as GPR88 agonists.

Jin C, Decker AM, Langston TL.

Bioorg Med Chem. 2017 Jan 15;25(2):805-812. doi: 10.1016/j.bmc.2016.11.058. Epub 2016 Dec 1.

27.

Axl is required for TGF-β2-induced dormancy of prostate cancer cells in the bone marrow.

Yumoto K, Eber MR, Wang J, Cackowski FC, Decker AM, Lee E, Nobre AR, Aguirre-Ghiso JA, Jung Y, Taichman RS.

Sci Rep. 2016 Nov 7;6:36520. doi: 10.1038/srep36520.

28.

Weight Loss Partially Restores Glucose-Driven Betatrophin Response in Humans.

Maurer L, Brachs S, Decker AM, Brachs M, Leupelt V, Jumpertz von Schwartzenberg R, Ernert A, Bobbert T, Krude H, Spranger J, Mai K.

J Clin Endocrinol Metab. 2016 Nov;101(11):4014-4020. Epub 2016 Jul 26.

PMID:
27459526
29.

The role of hematopoietic stem cell niche in prostate cancer bone metastasis.

Decker AM, Jung Y, Cackowski F, Taichman RS.

J Bone Oncol. 2016 Feb 19;5(3):117-120. eCollection 2016 Sep.

30.
31.

Mer Tyrosine Kinase Regulates Disseminated Prostate Cancer Cellular Dormancy.

Cackowski FC, Eber MR, Rhee J, Decker AM, Yumoto K, Berry JE, Lee E, Shiozawa Y, Jung Y, Aguirre-Ghiso JA, Taichman RS.

J Cell Biochem. 2017 Apr;118(4):891-902. doi: 10.1002/jcb.25768. Epub 2016 Nov 10.

32.

The Role of Occlusion in Implant Therapy: A Comprehensive Updated Review.

Sheridan RA, Decker AM, Plonka AB, Wang HL.

Implant Dent. 2016 Dec;25(6):829-838. Review.

PMID:
27749518
33.

DNMT1 Regulates Epithelial-Mesenchymal Transition and Cancer Stem Cells, Which Promotes Prostate Cancer Metastasis.

Lee E, Wang J, Yumoto K, Jung Y, Cackowski FC, Decker AM, Li Y, Franceschi RT, Pienta KJ, Taichman RS.

Neoplasia. 2016 Sep;18(9):553-66. doi: 10.1016/j.neo.2016.07.007.

34.

Design, synthesis, and pharmacological evaluation of JDTic analogs to examine the significance of replacement of the 3-hydroxyphenyl group with pyridine or thiophene bioisosteres.

Kormos CM, Gichinga MG, Runyon SP, Thomas JB, Mascarella SW, Decker AM, Navarro HA, Carroll FI.

Bioorg Med Chem. 2016 Aug 15;24(16):3842-8. doi: 10.1016/j.bmc.2016.06.029. Epub 2016 Jun 15.

35.

Identification of 2-({[1-(4-Fluorophenyl)-5-(2-methoxyphenyl)-1H-pyrazol-3-yl]carbonyl}amino)tricyclo[3.3.1.13,7]decane-2-carboxylic Acid (NTRC-844) as a Selective Antagonist for the Rat Neurotensin Receptor Type 2.

Thomas JB, Vivancos M, Giddings AM, Wiethe RW, Warner KR, Murza A, Besserer-Offroy É, Longpré JM, Runyon SP, Decker AM, Gilmour BP, Sarret P.

ACS Chem Neurosci. 2016 Sep 21;7(9):1225-31. doi: 10.1021/acschemneuro.6b00097. Epub 2016 Jul 13.

PMID:
27359371
36.

ANP system activity predicts variability of fat mass reduction and insulin sensitivity during weight loss.

Brachs M, Wiegand S, Leupelt V, Ernert A, Kintscher U, Jumpertz von Schwarzenberg R, Decker AM, Bobbert T, Hübner N, Chen W, Krude H, Spranger J, Mai K.

Metabolism. 2016 Jun;65(6):935-43. doi: 10.1016/j.metabol.2016.03.013. Epub 2016 Apr 7.

PMID:
27173472
37.

Growth Arrest-Specific 6 (GAS6) Promotes Prostate Cancer Survival by G1 Arrest/S Phase Delay and Inhibition of Apoptosis During Chemotherapy in Bone Marrow.

Lee E, Decker AM, Cackowski FC, Kana LA, Yumoto K, Jung Y, Wang J, Buttitta L, Morgan TM, Taichman RS.

J Cell Biochem. 2016 Dec;117(12):2815-2824. doi: 10.1002/jcb.25582. Epub 2016 Sep 26.

38.

Clinical outcomes of implant therapy in ectodermal dysplasia patients: a systematic review.

Wang Y, He J, Decker AM, Hu JC, Zou D.

Int J Oral Maxillofac Surg. 2016 Aug;45(8):1035-43. doi: 10.1016/j.ijom.2016.03.011. Epub 2016 Apr 2. Review.

PMID:
27052318
39.

Endogenous GAS6 and Mer receptor signaling regulate prostate cancer stem cells in bone marrow.

Jung Y, Decker AM, Wang J, Lee E, Kana LA, Yumoto K, Cackowski FC, Rhee J, Carmeliet P, Buttitta L, Morgan TM, Taichman RS.

Oncotarget. 2016 May 3;7(18):25698-711. doi: 10.18632/oncotarget.8365.

40.

Human Stem Cells Overexpressing miR-21 Promote Angiogenesis in Critical Limb Ischemia by Targeting CHIP to Enhance HIF-1α Activity.

Zhou Y, Zhu Y, Zhang L, Wu T, Wu T, Zhang W, Decker AM, He J, Liu J, Wu Y, Jiang X, Zhang Z, Liang C, Zou D.

Stem Cells. 2016 Apr;34(4):924-34. doi: 10.1002/stem.2321. Epub 2016 Feb 24.

41.

Regenerative Medicine for Periodontal and Peri-implant Diseases.

Larsson L, Decker AM, Nibali L, Pilipchuk SP, Berglundh T, Giannobile WV.

J Dent Res. 2016 Mar;95(3):255-66. doi: 10.1177/0022034515618887. Epub 2015 Nov 25. Review.

42.

Novel Synthesis and Pharmacological Characterization of NOP Receptor Agonist 8-[(1S,3aS)-2,3,3a,4,5,6-Hexahydro-1H-phenalen-1-yl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one (Ro 64-6198).

Chang SD, Brieaddy LE, Harvey JD, Lewin AH, Mascarella SW, Seltzman HH, Reddy PA, Decker AM, McElhinny CJ Jr, Zhong D, Peterson EE, Navarro HA, Bruchas MR, Carroll FI.

ACS Chem Neurosci. 2015 Dec 16;6(12):1956-64. doi: 10.1021/acschemneuro.5b00208. Epub 2015 Sep 30.

43.

Design, synthesis, and pharmacological evaluation of JDTic analogs to examine the significance of the 3- and 4-methyl substituents.

Carroll FI, Gichinga MG, Kormos CM, Maitra R, Runyon SP, Thomas JB, Mascarella SW, Decker AM, Navarro HA.

Bioorg Med Chem. 2015 Oct 1;23(19):6379-88. doi: 10.1016/j.bmc.2015.08.025. Epub 2015 Aug 25.

44.

The importance of the 6- and 7-positions of tetrahydroisoquinolines as selective antagonists for the orexin 1 receptor.

Perrey DA, Decker AM, Li JX, Gilmour BP, Thomas BF, Harris DL, Runyon SP, Zhang Y.

Bioorg Med Chem. 2015 Sep 1;23(17):5709-24. doi: 10.1016/j.bmc.2015.07.013. Epub 2015 Jul 16.

45.

A Prognosis System for Periimplant Diseases.

Decker AM, Sheridan R, Lin GH, Sutthiboonyapan P, Carroll W, Wang HL.

Implant Dent. 2015 Aug;24(4):416-21. doi: 10.1097/ID.0000000000000276.

PMID:
26035268
46.

Fast and slow interactions of n-alkanols with human 5-HT3A receptors: Implications for anesthetic mechanisms.

Decker AM, Witten S, Barann M, Urban BW.

Biochim Biophys Acta. 2015 Jul;1848(7):1524-35. doi: 10.1016/j.bbamem.2015.03.032. Epub 2015 Apr 8.

47.

Structure-activity relationships of substituted 1H-indole-2-carboxamides as CB1 receptor allosteric modulators.

Nguyen T, German N, Decker AM, Li JX, Wiley JL, Thomas BF, Kenakin TP, Zhang Y.

Bioorg Med Chem. 2015 May 1;23(9):2195-2203. doi: 10.1016/j.bmc.2015.02.058. Epub 2015 Mar 7.

48.

Effect of 1-substitution on tetrahydroisoquinolines as selective antagonists for the orexin-1 receptor.

Perrey DA, German NA, Decker AM, Thorn D, Li JX, Gilmour BP, Thomas BF, Harris DL, Runyon SP, Zhang Y.

ACS Chem Neurosci. 2015 Apr 15;6(4):599-614. doi: 10.1021/cn500330v. Epub 2015 Feb 12.

49.

Alpha-ethyltryptamines as dual dopamine-serotonin releasers.

Blough BE, Landavazo A, Partilla JS, Decker AM, Page KM, Baumann MH, Rothman RB.

Bioorg Med Chem Lett. 2014 Oct 1;24(19):4754-4758. doi: 10.1016/j.bmcl.2014.07.062. Epub 2014 Jul 29.

50.

Diarylureas as allosteric modulators of the cannabinoid CB1 receptor: structure-activity relationship studies on 1-(4-chlorophenyl)-3-{3-[6-(pyrrolidin-1-yl)pyridin-2-yl]phenyl}urea (PSNCBAM-1).

German N, Decker AM, Gilmour BP, Gay EA, Wiley JL, Thomas BF, Zhang Y.

J Med Chem. 2014 Sep 25;57(18):7758-69. doi: 10.1021/jm501042u. Epub 2014 Sep 4.

Supplemental Content

Loading ...
Support Center